Stock listing
LSE:0XOD UroGen Pharma Ltd. Share Price
UK listing (LSE) of UroGen Pharma Ltd. · home listing NASDAQ:URGN
Follow UroGen Pharma Ltd. into a list and get an email when it puts out news.
Share price · LSE:0XOD
$31.83 USD -0.09 (-0.3%)
Close on Nov 20, 2026
- Day range
- $30.57 – $31.83 USDNov 20, 2026
- Volume
- 666 sharesNov 20, 2026
- 52-week range
- $16.19 – $51.11 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $32,130 USDMedian day 330 shares · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:URGN · Home | $27.65 USD | -2.14 (-7.2%) | 2,399,078 | $31.15 | $31.90 | $27.58 | $29.79 | Close on Nov 20, 2026 |
| LSE:0XOD | $31.83 USD | -0.086 (-0.3%) | 666 | $31.20 | $31.83 | $30.57 | $31.92 | Close on Nov 20, 2026 |
| Frankfurt:UR8 | €27.86 EUR | -1.01 (-3.5%) | — | €28.17 | €28.17 | €27.86 | €28.87 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · LSE:0XOD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $24.65 | -1.45 | -5.6% | $25.90 | $26.30 | $24.57 | 6,418 | |
| $26.10 | -3.16 | -10.8% | $28.02 | $28.54 | $25.98 | 1,495 | |
| $29.26 | -5.395 | -15.6% | $33.61 | $33.64 | $27.97 | 1,675 | |
| $34.66 | +0.42 | +1.2% | $35.18 | $35.18 | $34.15 | 1,646 | |
| $34.24 | +1.416 | +4.3% | $32.72 | $34.66 | $32.51 | 211 | |
| $32.82 | -0.291 | -0.9% | $32.55 | $33.48 | $32.51 | 1,718 | |
| $33.11 | -0.684 | -2.0% | $34.66 | $34.66 | $33.11 | 1,308 | |
| $33.79 | -0.106 | -0.3% | $34.35 | $34.35 | $33.42 | 1,784 | |
| $33.90 | -0.873 | -2.5% | $34.20 | $34.50 | $33.50 | 230 | |
| $34.77 | -0.177 | -0.5% | $34.73 | $34.87 | $33.50 | 67 | |
| $34.95 | +0.471 | +1.4% | $34.53 | $34.95 | $34.34 | 128 | |
| $34.48 | -1.211 | -3.4% | $35.40 | $35.40 | $34.46 | 187 | |
| $35.69 | +0.51 | +1.4% | $34.45 | $36.23 | $34.45 | 42 | |
| $35.18 | +1.276 | +3.8% | $33.95 | $35.18 | $33.77 | 29 | |
| $33.91 | -0.805 | -2.3% | $34.97 | $35.00 | $33.50 | 271 | |
| $34.71 | -1.87 | -5.1% | $36.35 | $37.49 | $34.64 | 12 | |
| $36.58 | -1.955 | -5.1% | $37.50 | $38.52 | $36.58 | 181 | |
| $38.53 | +0.285 | +0.7% | $38.20 | $38.53 | $37.94 | 531 | |
| $38.25 | +0.509 | +1.4% | $38.38 | $38.39 | $38.23 | 29 | |
| $37.74 | +0.30 | +0.8% | $36.65 | $37.96 | $36.29 | 46 | |
| $37.44 | -0.14 | -0.4% | $37.16 | $37.81 | $36.59 | 301 | |
| $37.58 | -3.769 | -9.1% | $40.05 | $40.05 | $34.20 | 2,611 | |
| $41.35 | -0.411 | -1.0% | $42.05 | $42.05 | $41.35 | 163 | |
| $41.76 | +0.16 | +0.4% | $43.50 | $44.00 | $41.54 | 301 | |
| $41.60 | +1.189 | +2.9% | $41.38 | $42.30 | $41.30 | 183 | |
| $40.41 | -0.02 | 0.0% | $40.82 | $40.85 | $40.40 | 25 | |
| $40.43 | -0.285 | -0.7% | $40.63 | $41.26 | $40.20 | 40 | |
| $40.72 | +0.535 | +1.3% | $40.39 | $40.97 | $40.39 | 1,851 | |
| $40.18 | -0.80 | -2.0% | $40.61 | $40.61 | $39.92 | 27 | |
| $40.98 | -0.03 | -0.1% | $42.01 | $42.01 | $40.95 | 32 | |
| $41.01 | -0.10 | -0.2% | $42.15 | $42.15 | $41.01 | 6 | |
| $41.11 | +0.35 | +0.9% | $41.26 | $41.31 | $40.47 | 666 | |
| $40.76 | -2.40 | -5.6% | $42.83 | $42.83 | $39.70 | 703 | |
| $43.16 | +0.13 | +0.3% | $44.00 | $44.38 | $43.16 | 10 | |
| $43.03 | -0.41 | -0.9% | $43.25 | $44.96 | $43.02 | 1,166 | |
| $43.44 | -0.06 | -0.1% | $43.88 | $43.88 | $43.29 | 2,651 | |
| $43.50 | +0.37 | +0.9% | $43.00 | $45.21 | $43.00 | 877 | |
| $43.13 | +1.88 | +4.6% | $42.90 | $43.17 | $42.41 | 5,630 | |
| $41.25 | -1.91 | -4.4% | $43.25 | $43.25 | $41.00 | 411 | |
| $43.16 | +0.395 | +0.9% | $42.91 | $43.54 | $42.25 | 44 | |
| $42.77 | +0.535 | +1.3% | $43.03 | $43.04 | $41.68 | 183 | |
| $42.23 | -3.20 | -7.0% | $43.50 | $44.13 | $42.23 | 654 | |
| $45.43 | +1.20 | +2.7% | $43.50 | $47.07 | $43.50 | 2,459 | |
| $44.23 | +0.50 | +1.1% | $44.00 | $44.23 | $43.00 | 147 | |
| $43.73 | -1.49 | -3.3% | $44.03 | $44.38 | $43.65 | 400 | |
| $45.22 | +1.42 | +3.2% | $44.36 | $45.51 | $43.63 | 370 | |
| $43.80 | +0.48 | +1.1% | $42.12 | $45.14 | $42.12 | 423 | |
| $43.32 | -0.541 | -1.2% | $42.59 | $43.57 | $42.59 | 119 | |
| $43.86 | -1.939 | -4.2% | $45.18 | $45.80 | $43.37 | 1,792 | |
| $45.80 | -0.385 | -0.8% | $45.50 | $47.17 | $44.79 | 225 | |
| $46.18 | -0.165 | -0.4% | $47.00 | $47.00 | $45.35 | 366 | |
| $46.35 | -0.615 | -1.3% | $46.85 | $47.17 | $45.90 | 330 | |
| $46.97 | -0.173 | -0.4% | $46.21 | $47.17 | $45.26 | 882 | |
| $47.14 | +0.688 | +1.5% | $47.36 | $47.40 | $45.60 | 422 | |
| $46.45 | -4.05 | -8.0% | $51.00 | $51.11 | $46.31 | 2,175 |
- Ticker
- LSE:0XOD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LSE
- Currency
- USD
What changed lately
Latest news release · Nov 4, 2026
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
Latest earnings call · Nov 4, 2026
UroGen Pharma (NASDAQ:URGN) Q3 2026 Earnings Call
Replay and transcript
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 30 slides
Latest news
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
Nov 4, 2026
Closed $29.26 (-15.6%) on Nov 4, 2026
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
Nov 3, 2026
Closed $34.66 (+1.2%) on Nov 3, 2026
UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
Nov 2, 2026
Closed $34.24 (+4.3%) on Nov 2, 2026
UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
Oct 28, 2026
Closed $33.79 (-0.3%) on Oct 28, 2026
UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026
Oct 27, 2026
Closed $33.79 (-0.3%) on Oct 28, 2026
UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC
Oct 19, 2026
Closed $33.91 (-2.3%) on Oct 19, 2026
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
Aug 20, 2026
Closed $46.45 (-8.0%) on Aug 20, 2026
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
Aug 20, 2026
Closed $46.45 (-8.0%) on Aug 20, 2026
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
Aug 17, 2026
Closed $48.98 (+2.1%) on Aug 17, 2026
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
Aug 5, 2026
Closed $46.06 (+15.8%) on Aug 5, 2026
UroGen Pharma Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 31 in the last 12 months · 205 in all · newest Nov 4, 2026 · oldest 2019
- Calls
- 26 calls with a replay · 26 with a transcript · latest Nov 4, 2026
- Decks
- 10 decks · latest August 2026
Where UroGen Pharma Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:URGN · Home listing | NASDAQ | United States | USD |
| LS Exchange:A2DTCV | LS Exchange | Germany | EUR |
| gettex:UR8 | gettex | Germany | EUR |
| Lang & Schwarz:A2DTCV | Lang & Schwarz | Germany | EUR |
| LSE:0XOD · This page | LSE | United Kingdom | USD |
| BOATS:URGN | BOATS | United States | USD |
| Frankfurt:UR8 | Frankfurt | Germany | EUR |
| Dusseldorf:UR8 | Dusseldorf | Germany | EUR |
| Munich:UR8 | Munich | Germany | EUR |
| Stuttgart:UR8 | Stuttgart | Germany | EUR |
| Tradegate:UR8 | Tradegate | Germany | EUR |
Valuation
EV/sales 5.8× against a median of 41.7×: 3rd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.46B USD
- P/E
- Loss
- EV/sales
- 5.8×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 91.4%
- Operating margin
- −12.4%
- Net margin
- −26.3%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.23
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| UroGen Pharma Ltd. · NASDAQ:URGN | US$1.36B | US$1.46B | n/a | 5.8× | n/a | n/a | −26.3% | n/a | 1.23 |
| ADARx Pharmaceuticals, Inc. · NASDAQ:ADRX | US$1.42B | US$521.8M | n/a | 77.6× | n/a | 2.5× | n/a | 0.0× | n/a |
| Nurix Therapeutics, Inc. · NASDAQ:NRIX | US$1.40B | US$683.6M | 4.8× | 1.0× | n/a | 1.4× | 42.0% | 0.0× | 1.15 |
| Intellia Therapeutics, Inc. · NASDAQ:NTLA | US$1.40B | US$1.00B | n/a | 19.0× | n/a | 2.3× | −805.7% | 0.1× | 2.01 |
| Tyra Biosciences, Inc. · NASDAQ:TYRA | US$1.39B | US$694.9M | n/a | n/a | n/a | 2.0× | n/a | 0.0× | 0.40 |
| Wuhan Healthgen Biotechnology Corp Class A · SSE:688765 | US$1.37B | US$1.37B | n/a | 164× | n/a | 3.3× | −252.8% | 0.1× | n/a |
| Rapport Therapeutics, Inc. · NASDAQ:RAPP | US$1.37B | US$987.3M | n/a | 49.4× | n/a | 3.5× | −752.4% | 0.0× | 1.16 |
| Immunocore Holdings plc · NASDAQ:IMCR | US$1.36B | US$463.6M | n/a | 1.1× | n/a | 3.3× | −7.5% | 0.0× | 0.62 |
| Nanobiotix SA · EURONEXT:NANO | US$1.36B | US$1.36B | n/a | 41.7× | n/a | n/a | −80.8% | n/a | n/a |
| uniQure N.V. · NASDAQ:QURE | US$1.36B | US$739.1M | n/a | 36.6× | n/a | 4.6× | n/a | 0.2× | 1.25 |
| OliX Pharmaceuticals, Inc. · KRX:226950 | US$1.31B | US$1.16B | n/a | 114× | n/a | 7.4× | −102.9% | 0.1× | n/a |
| Median of the others | US$1.37B | US$863.2M | 4.8× | 41.7× | 3.3× | −102.9% | 0.0× | 1.15 |
Forecasts
6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 60.71 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.37 · 7 analysts
- Revenue, year to Dec 2026
- 319.6M · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Liz Barrett | President and Chief Executive Officer |
| Chris Degnan | Chief Financial Officer |
| Jason Smith | General Counsel and Chief Compliance Officer |
| Cindy Romano | Director, Corporate Communications |
| Vincent Perrone | Senior Director, Investor Relations |
| Alison Hardgrove | SVP, Human Resources |
| Jim Ottinger | EVP, Regulatory Affairs and Quality |
| Marina Konorty | EVP, Research & Development and Technical Operations |
| Timothy Simon | SVP, Business Development and Portfolio Strategy |
| Mark P. Schoenberg | Chief Medical Officer |
| Michael J. Louie | Chief Development Officer |
Board
| Director | Role |
|---|---|
| Arie Belldegrun | Member of the Compensation Committee |
| Cynthia M. Butitta | of the Audit Committee |
| Daniel Wildman | of the Compensation Committee; of the Compliance Committee |
| Jim Robinson | Director |
| Leana S. Wen | of the Audit Committee; of the Nominating and Corporate Governance Committee |
| Stuart Holden | of the Audit Committee; of the Compliance Committee |
Events
Calls
| Call | When | Status |
|---|---|---|
| UroGen Pharma (NASDAQ:URGN) Q3 2026 Earnings Call | Wed, Nov 04, 2026 · 10:00 AM ET | Replay |
| UroGen Pharma (NASDAQ:URGN) Q2 2026 Earnings Call | Wed, Aug 05, 2026 · 10:00 AM ET | Replay |
| UroGen Pharma (NASDAQ:URGN) Q1 2026 Earnings Call | Wed, May 06, 2026 · 10:00 AM ET | Replay |
| UroGen Pharma (NASDAQ:URGN) Q4 2025 Earnings Call | Mon, Mar 02, 2026 · 10:00 AM ET | Replay |
| UroGen Pharma (NASDAQ:URGN) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 10:00 AM ET | Replay |
| UroGen Pharma (NASDAQ:URGN) Q1 2025 Earnings Call | Mon, May 12, 2025 · 10:00 AM ET | Replay |
| UroGen Pharma (NASDAQ:URGN) Q4 2024 Earnings Call | Mon, Mar 10, 2025 · 10:00 AM ET | Replay |
| UroGen Pharma (NASDAQ:URGN) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 10:00 AM ET | Replay |
| UroGen Pharma (NASDAQ:URGN) Q2 2024 Earnings Call | Tue, Aug 13, 2024 · 10:00 AM ET | Replay |
| UroGen Pharma (NASDAQ:URGN) Q1 2024 Earnings Call | Mon, May 13, 2024 · 10:00 AM ET | Replay |
All 26 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · Before open | −16.4% |
| Q2 2026 | Aug 5, 2026 · Before open | +16.3% |
| Q1 2026 | May 6, 2026 · Before open | +10.2% |
| Q4 2025 | Mar 2, 2026 | −13.3% |
| Q3 2025 | Nov 6, 2025 · Before open | +21.9% |
| Q2 2025 | Aug 7, 2025 · Before open | −7.1% |
| Q1 2025 | May 12, 2025 · Before open | +7.3% |
| Q4 2024 | Mar 12, 2025 · Before open | 0.0% |
| Q3 2024 | Nov 6, 2024 · Before open | +0.3% |
| Q2 2024 | Aug 13, 2024 · Before open | +3.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · Before open | +2.6% |
| Q4 2023 | Mar 14, 2024 · Before open | −18.0% |
| Q3 2023 | Nov 14, 2023 · Before open | −0.7% |
| Q2 2023 | Aug 10, 2023 · Before open | +2.5% |
| Q1 2023 | May 11, 2023 · Before open | +8.0% |
| Q4 2022 | Mar 16, 2023 · Before open | −3.1% |
| Q3 2022 | Nov 10, 2022 · Before open | −16.3% |
| Q2 2022 | Aug 11, 2022 · Before open | −6.5% |
| Q1 2022 | May 10, 2022 · Before open | +6.0% |
| Q4 2021 | Mar 21, 2022 · Before open | +0.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 30 slides | August 2026 |
| Investor Presentation (January 2025) | Investor deck | 44 slides | Jan 14, 2025 |
| Technical Presentation (June 2024) | Technical | 57 slides | Jun 13, 2024 |
| Investor Presentation (March 2024) | Investor deck | 56 slides | Mar 4, 2024 |
| Investor Presentation (February 2024) | Investor deck | 53 slides | Feb 7, 2024 |
| Technical Presentation (July 2023) | Technical | 84 slides | Jul 27, 2023 |
| Technical Presentation (July 2023) | Technical | 17 slides | Jul 27, 2023 |
| J.P. Morgan 2021 Healthcare Conference | Conference | 29 slides | Jan 11, 2021 |
| Investor Day (September 2019) | Investor day | 68 slides | Sep 24, 2019 |
| Investor Presentation (January 2018) | Investor deck | 25 slides | Jan 8, 2018 |
Financings
| Raise | Date |
|---|---|
| Strategic investment of equity securities Announced: up to US$7M Buyers: UroGen Pharma Ltd. (up to $7 million in the equity securities of IntraGel) Use of proceeds: Phase 2 clinical development of TumoCure for advanced head and neck cancer | Aug 20, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$13.00 a share on May 3, 2017.
- Price
- US$13.00 a share
- Shares offered
- 4,473,373 ordinary shares
- Offering size
- US$58.2 million
- Underwriters' option
- Up to 671,005 more shares
- Underwriters
- Jefferies, Cowen and Company, Raymond James, Oppenheimer & Co. · In the order on the cover
- Shares delivered
- On or about May 9, 2017
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 4, 2016 |
| Filed publicly | Apr 7, 2017 |
| Amended once | Apr 24, 2017 |
| Shares registered with an exchange | May 1, 2017 |
| Declared effective by the SEC | May 3, 2017 |
| Final prospectus, with the price | May 5, 2017 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | May 5, 2017 |
| EFFECT · Notice that a registration is effective | May 3, 2017 |
| F-1MEF · Registration of more shares for the same offering | May 3, 2017 |
| CERTNAS · Nasdaq's certificate of listing | May 2, 2017 |
| CORRESP · Letter to the SEC | May 1, 2017 |
| CORRESP · Letter to the SEC | May 1, 2017 |
| 8-A12B · Registration of shares for listing on an exchange | May 1, 2017 |
| F-1/A · Registration statement, amended | Apr 24, 2017 |
| CORRESP · Letter to the SEC | Apr 19, 2017 |
| F-1 · Registration statement | Apr 7, 2017 |
All 28 filings
| Filing | Filed |
|---|---|
| DRSLTR · Letter to the SEC with a draft | Mar 31, 2017 |
| DRS/A · Draft registration statement, amended | Mar 31, 2017 |
| UPLOAD · Letter from the SEC | Mar 16, 2017 |
| DRS/A · Draft registration statement, amended | Mar 9, 2017 |
| DRSLTR · Letter to the SEC with a draft | Mar 8, 2017 |
| UPLOAD · Letter from the SEC | Jan 12, 2017 |
| DRSLTR · Letter to the SEC with a draft | Dec 28, 2016 |
| DRS/A · Draft registration statement, amended | Dec 28, 2016 |
| UPLOAD · Letter from the SEC | Dec 21, 2016 |
| DRS/A · Draft registration statement, amended | Dec 7, 2016 |
| DRS/A · Draft registration statement, amended | Jun 7, 2016 |
| DRSLTR · Letter to the SEC with a draft | May 17, 2016 |
| DRS/A · Draft registration statement, amended | May 17, 2016 |
| UPLOAD · Letter from the SEC | May 9, 2016 |
| DRSLTR · Letter to the SEC with a draft | Apr 20, 2016 |
| DRS/A · Draft registration statement, amended | Apr 20, 2016 |
| UPLOAD · Letter from the SEC | Apr 1, 2016 |
| DRS · Draft registration statement | Mar 4, 2016 |
Open IPO · From the cover of the final prospectus (424B4) filed May 5, 2017
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 109.8M | 90.4M | 82.7M | 64.4M | 48.0M | 11.8M | 18.0K | 1.13M | 8.16M | 17.5M |
| Cost of revenue | 12.4M | 8.88M | 9.36M | 7.65M | 5.16M | 1.01M | 48.0K | 1.80M | 600.0K | 28.0K |
| Gross profit | 97.3M | 81.5M | 73.4M | 56.7M | 42.9M | 10.8M | 18.0K | -675.0K | 7.56M | 17.5M |
| Research and development | 67.1M | 57.1M | 45.6M | 52.9M | 47.6M | 47.3M | 49.3M | 36.9M | 18.7M | 10.3M |
| Selling, general and administrative | 155.1M | 121.2M | 93.3M | 82.8M | 87.5M | 90.2M | 60.2M | 39.6M | 8.81M | 6.42M |
| Operating income | -124.9M | -96.8M | -65.5M | -79.0M | -92.3M | -126.7M | -109.5M | -77.2M | -19.9M | 798.0K |
| Depreciation and amortization | 307.0K | 329.0K | 802.0K | 924.0K | 831.0K | 416.0K | 300.0K | 400.0K | 200.0K | 200.0K |
| EBITDA | -124.6M | -96.5M | -64.7M | -78.1M | -91.5M | -126.3M | -109.2M | -76.8M | -19.8M | 998.0K |
| Interest expense | 33.8M | 12.5M | 14.7M | 8.44M | 17.4M | 3.67M | 284.0K | 0 | 0 | 0 |
| Income before tax | -153.4M | -124.0M | -98.3M | -108.0M | -109.4M | -125.1M | -105.1M | -75.5M | -20.0M | -1.94M |
| Income tax | 78.0K | 2.83M | 3.92M | 1.75M | 1.45M | 3.37M | -4.62M | 125.0K | 19.0K | 0 |
| Net income | -153.5M | -126.9M | -102.2M | -109.8M | -110.8M | -128.5M | -105.1M | -75.7M | -20.0M | -1.94M |
| Earnings per share, basic | -3.19 | -2.96 | -3.55 | -4.81 | -4.96 | -5.90 | -5.12 | -4.80 | -2.14 | -1.91 |
| Earnings per share, diluted | -4.96 | -5.90 | -5.12 | -4.80 | -2.14 | -1.91 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 110.7M | 172.0M | 95.0M | 55.4M | 44.4M | 52.9M | 49.7M | 101.3M | 37.0M | 21.4M |
| Short-term investments | 49.3M | 110.7M | 56.2M | 44.6M | 44.8M | 49.2M | 97.4M | 36.0M | 95.0K | |
| Receivables | 33.1M | 20.3M | 15.4M | 12.7M | 11.7M | 7.05M | 198.0K | 83.0K | ||
| Inventory | 16.5M | 9.23M | 5.67M | 4.33M | 4.83M | 1.96M | 316.0K | 105.0K | ||
| Current assets | 186.0M | 276.1M | 169.2M | 128.9M | 114.4M | 115.6M | 148.6M | 102.2M | 74.5M | 22.0M |
| Property, plant and equipment | 637.0K | 655.0K | 689.0K | 1.30M | 1.97M | 2.05M | 977.0K | 948.0K | 805.0K | 741.0K |
| Total assets | 200.5M | 285.7M | 178.3M | 135.6M | 119.7M | 122.0M | 202.4M | 103.6M | 75.5M | 23.1M |
| Accounts payable | 12.1M | 10.9M | 6.51M | 5.53M | 5.79M | 3.27M | 4.69M | 4.27M | 2.84M | 1.88M |
| Current liabilities | 46.4M | 45.9M | 31.2M | 23.9M | 22.4M | 21.4M | 19.5M | 13.5M | 7.04M | 3.14M |
| Long-term debt | 122.2M | 121.7M | 98.6M | 97.5M | 0 | 3.61M | ||||
| Total debt | 125.0M | 121.7M | 98.6M | 97.5M | 0 | 1.50M | 2.60M | |||
| Total liabilities | 305.9M | 294.5M | 243.5M | 225.0M | 111.3M | 25.6M | 22.1M | 13.5M | 7.04M | 6.75M |
| Shareholders' equity | -105.5M | -8.80M | -65.2M | -89.4M | 8.41M | 96.4M | 180.3M | 90.1M | 68.5M | 16.3M |
| Shares outstanding | 48.4M | 42.2M | 32.5M | 23.1M | 22.5M | 22.2M | 21.0M | 16.2M | 13.8M | 2.31M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -162.4M | -96.8M | -76.4M | -87.6M | -84.9M | -105.9M | -71.0M | -37.3M | -9.57M | 4.19M |
| Capital spending | -289.0K | -295.0K | -194.0K | -254.0K | -752.0K | -1.22M | -325.0K | -560.0K | -271.0K | -695.0K |
| Free cash flow | -162.7M | -97.1M | -76.6M | -87.8M | -85.6M | -107.1M | -71.3M | -37.9M | -9.84M | 3.49M |
| Cash from investing | 61.6M | -20.6M | -953.0K | 1.06M | 4.07M | 93.2M | -145.6M | 35.3M | -36.3M | -719.0K |
| Cash from financing | 39.9M | 194.6M | 116.9M | 97.1M | 72.3M | 16.5M | 165.3M | 66.4M | 61.6M | -9.00K |
| Share buybacks | 1.35M | -83.0K | 16.5M | 165.3M | 66.6M | 61.6M | 570.0K | |||
| Change in cash | -61.0M | 77.2M | 39.6M | 10.6M | -8.50M | 3.88M | -51.4M | 64.4M | 15.7M | 3.46M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Nov 4, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 9, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Sep 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 20, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 20, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2026 | Management or board change | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 9, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 2, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | May 27, 2026 | Annual report | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 8, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 27, 2026 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Mar 2, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 2, 2026 | Results | SEC |
| 8-K · Current report | Mar 2, 2026 | Material contract | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 19, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Nov 6, 2025 | Offer document | SEC |
| S-3ASR · Registration statement | Nov 6, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 27, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 29, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Jul 16, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Jul 15, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jul 3, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 16, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 10, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 9, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 17, 2025 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 10, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2025 | Results | SEC |
| 8-K · Current report | Feb 20, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 14, 2025 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 18, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 6, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Oct 24, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 9, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 9, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 9, 2024 | Management or board change | SEC |
| 8-K · Current report | Sep 24, 2024 | Financing | SEC |
| 8-K · Current report | Sep 13, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Sep 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 10, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 15, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Aug 13, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 8-K · Current report | Aug 8, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Jul 9, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jul 1, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 1, 2024 | Meeting notice | SEC |
| SC 13G · Big-stake notice | Jun 24, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jun 24, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jun 18, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jun 18, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Jun 17, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 13, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 11, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | May 8, 2024 | Big-stake notice | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 20, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 18, 2024 | Other filings | SEC |
| 10-K · Annual report | Mar 14, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 14, 2024 | Results | SEC |
| 8-K · Current report | Mar 4, 2024 | Current report | SEC |
| 8-K · Current report | Mar 1, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 22, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Feb 12, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Feb 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 7, 2024 | Current report | SEC |
| 4/A · Change in ownership, amended | Feb 5, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 2, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 1, 2024 | Other filings | SEC |
| 8-K · Current report | Jan 17, 2024 | Material contract | SEC |
| 8-K · Current report | Jan 2, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Dec 29, 2023 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Dec 5, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 27, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 16, 2023 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Nov 14, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
This page holds 200 of 584 filings. Open Filings
Cap table
Built by 6ix from UroGen Pharma Ltd.’s releases · as of Aug 20, 2026
- Common shares
- 49,047,823
- Fully diluted
- 49,047,823
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 49,047,823 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 49,047,823 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Kathryn Falberg Other companies: Nuvation Bio Inc. (Board of Directors · Since at least Feb 10, 2021); Arcus Biosciences, Inc. (Board Member · Since at least Mar 14, 2018); The Trade Desk, Inc. (Director · Since at least Sep 20, 2016); Tricida Inc (Director · Jun 27, 2018 – Jun 15, 2022 · Past); Sio Gene Therapies Inc (Director · Apr 7, 2017 – May 15, 2017 · Past); BioMarin Pharmaceutical Inc. (Director · Jul 15, 2016 – Jul 15, 2016 · Past); Aimmune Therapeutics Inc (Director · Aug 5, 2015 – Oct 10, 2020 · Past); aTyr Pharma, Inc. (Director · May 6, 2015 – May 24, 2016 · Past); Medivation Inc (Director · Jan 31, 2013 – Sep 28, 2016 · Past); Jazz Pharmaceuticals plc (EVP and CFO · Dec 1, 2009 – Mar 5, 2014 · Past); Novelion Therapeutics Inc (Director · Mar 25, 2009 – May 26, 2011 · Past); Oruka Therapeutics, Inc. (CFO and COO · Feb 23, 2009 – Jun 25, 2009 · Past); Halozyme Therapeutics, Inc. (Director · May 15, 2007 – May 4, 2016 · Past) | Director · Jan 1, 2019 – Jun 7, 2021 · Past |
| Peter P Pfreundschuh Other companies: Y mAbs Therapeutics (EVP, CFO and Treasurer · Since at least Jun 28, 2024); Voyager Therapeutics, Inc. (Chief Financial Officer · Sep 19, 2022 – Feb 21, 2024 · Past); Korro Bio, Inc. (Chief Financial Officer · Dec 1, 2020 – Feb 18, 2022 · Past); Sucampo Pharmaceuticals Inc (CFO · Mar 20, 2017 – Feb 13, 2018 · Past); Immunomedics Inc (Chief Financial Officer · Aug 20, 2015 – Aug 20, 2015 · Past) | Chief Financial Officer · Jan 1, 2019 – Oct 15, 2020 · Past |
| Shawn Tomasello Other companies: Cabaletta Bio, Inc. (Director · Since at least Jul 21, 2023); 4D Molecular Therapeutics, Inc. (Director · Since at least Dec 10, 2020); Kalaris Therapeutics, Inc. (Director · Mar 29, 2022 – Jun 6, 2024 · Past); Gamida Cell Ltd (Director · Jan 1, 2022 – Jan 31, 2024 · Past); Tcr2 Therapeutics Inc (Director · Feb 3, 2021 – Jun 1, 2023 · Past) | Director · Jun 7, 2021 – Jun 7, 2021 · Past |
| Cynthia M. Butitta Other companies: Autolus Therapeutics plc (Chair of the Compensation Committee, Member of the Audit Committee · Since at least Mar 18, 2026); Century Therapeutics, Inc. (Director · Since at least Jun 17, 2021); Olema Pharmaceuticals, Inc. (Director · Since at least Aug 12, 2020); Kite Pharma Inc (Chief Operating Officer · Jun 19, 2014 – Oct 3, 2017 · Past) | of the Audit Committee · Since at least Jan 1, 2019 |
| James A Robinson Jr Other companies: Eledon Pharmaceuticals, Inc. (Director · Since at least Oct 1, 2023); Urovant Sciences Ltd (PEO;CEO/Urovant Sciences, Inc., Director · Mar 1, 2019 – Mar 29, 2021 · Past); Neos Therapeutics Inc (Director · Jan 29, 2019 – Mar 19, 2021 · Past); Alkermes plc (President & COO,Alkermes, Inc. · Mar 5, 2018 – Apr 4, 2019 · Past) | Director · Since at least Jul 25, 2023 |
| Molly Henderson Other companies: Phathom Pharmaceuticals, Inc. (CFO and CBO · Apr 5, 2022 – Apr 7, 2025 · Past); Advaxis Inc (Executive Vice President & CFO · Jun 6, 2018 – May 4, 2020 · Past); Iovance Biotherapeutics, Inc. (CFO · Jun 8, 2015 – Jun 1, 2016 · Past); VirtualScopics Inc (Chief Business/Financial Off. · May 30, 2006 – Jan 29, 2013 · Past) | Chief Financial Officer · Oct 1, 2020 – Jan 31, 2022 · Past |
| Arie Belldegrun Other companies: Allogene Therapeutics, Inc. (Director · Since at least Mar 26, 2021); Kronos Bio Inc (Director · Since at least Oct 8, 2020); Ginkgo Bioworks Holdings, Inc. (Director · Sep 16, 2021 – Jun 12, 2024 · Past) | Director · Since at least Mar 24, 2021 |
| Elizabeth A Barrett Other companies: Sage Therapeutics Inc (Director · Since at least Jun 11, 2025); Allogene Therapeutics, Inc. (Director · Since at least Jul 30, 2021); LifeSci Acquisition II Corp (Director · Nov 20, 2020 – Nov 20, 2020 · Past) | Chief Executive Officer · Since at least Jan 3, 2019 |
| Chris Degnan Other companies: Galera Therapeutics, Inc. (Chief Financial Officer · Nov 6, 2019 – Mar 13, 2023 · Past); Verrica Pharmaceuticals Inc. (Chief Financial Officer · Jun 14, 2018 – Feb 28, 2019 · Past) | Chief Financial Officer · Since at least Oct 8, 2024 |
| Dong Kim Other companies: Canton Strategic Holdings, Inc. (CFO · Mar 27, 2025 – Mar 27, 2025 · Past) | Chief Financial Officer · Mar 25, 2022 – Sep 9, 2024 · Past |
All 26 people
| Person | Seat |
|---|---|
| Leana S. Wen Other companies: Glaukos Corporation (Director · Since at least Mar 1, 2021) | Director · Since at least Sep 8, 2022 |
| Liz Barrett Other companies: Allogene Therapeutics, Inc. (President and Chief Executive Officer of UroGen, Former CEO of Novartis Oncology · Since at least Nov 6, 2026) | President and Chief Executive Officer · Since at least Nov 4, 2026 |
| Alison Hardgrove | SVP, Human Resources · Since at least Nov 5, 2026 |
| Chris Degnan | Chief Financial Officer · Since at least Mar 2, 2026 |
| Cindy Romano | Director, Corporate Communications · Since at least Nov 3, 2026 |
| Daniel Wildman | of the Compensation Committee; of the Compliance Committee · Since at least Nov 5, 2026 |
| Jason Smith | General Counsel and Chief Compliance Officer · Since at least Aug 31, 2020 |
| Jim Ottinger | EVP, Regulatory Affairs and Quality · Since at least Nov 4, 2026 |
| Jim Robinson | Director · Since at least Aug 28, 2026 |
| Marina Konorty | EVP, Research & Development and Technical Operations · Since at least Nov 5, 2026 |
| Mark P. Schoenberg | Chief Medical Officer · Since at least Jan 1, 2019 |
| Michael J. Louie | Chief Development Officer · Since at least Jul 7, 2025 |
| Stephen Mullennix | Chief Operating Officer · Jan 1, 2019 – Apr 26, 2020 · Past |
| Stuart Holden | of the Audit Committee; of the Compliance Committee · Since at least Jan 1, 2019 |
| Timothy Simon | SVP, Business Development and Portfolio Strategy · Since at least Nov 5, 2026 |
| Vincent Perrone | Senior Director, Investor Relations · Since at least Nov 3, 2026 |
Log in to ask 6ix AI your own questions about UroGen Pharma Ltd.